羟丙基-β-环糊精佐剂四价季节性流感疫苗的安全性与免疫原性:一项1期临床试验
本研究为单盲随机1期临床试验,纳入36名健康成人,按2:1随机接受含9 μg血凝素(HA)/株和20% w/v羟丙基-β-环糊精(HP-β-CyD)的四价季节性流感疫苗(FluCyD-vac,n=24)或含15 μg HA/株的标准四价季节性流感疫苗(Flu-vac,n=12)单剂接种。FluCyD-vac耐受良好,接种后21天血凝抑制(HI)滴度与Flu-vac相当且满足国际标准,尽管HA抗原量减少40%;FluCyD-vac组经四种HA抗原刺激后产肿瘤坏死因子(TNF)-α的CD4+ T细胞增强。
要点
- FluCyD-vac组报告的不良事件多为注射部位轻度局部皮肤反应,两组均未报告严重不良事件。
- 接种后21天,FluCyD-vac组HI滴度与Flu-vac组相当,尽管HA抗原量减少40%。
- 四种HA抗原刺激后,FluCyD-vac组产TNF-α的CD4+ T细胞增强。
核心结论
- FluCyD-vac耐受良好且具有免疫原性,尽管所含HA抗原比Flu-vac少40%。
- 本研究表明HP-β-CyD是一种潜在安全的新型人用流感疫苗佐剂。
研究设计与样本
- 单盲随机1期临床试验,纳入36名健康成人志愿者。
- 参与者按2:1随机接受单剂FluCyD-vac(含9 μg HA/株和20% w/v HP-β-CyD,n=24)或Flu-vac(仅含15 μg HA/株,n=12)。
- 评估征集性和非征集性不良事件,采用血凝抑制(HI)滴度评估免疫应答,并用流式细胞术评估外周血单核细胞(PBMC)经HA疫苗株刺激后的T细胞功能。
主要发现
- FluCyD-vac耐受良好,征集性不良事件多为注射部位轻度局部皮肤反应,两组均未报告严重不良事件。
- 接种后21天,FluCyD-vac组HI滴度与Flu-vac组相当,尽管HA抗原剂量减少,仍足以满足国际标准。
- PBMC经疫苗中四种HA抗原刺激后,FluCyD-vac组产TNF-α的CD4+ T细胞增强。
关键数值与推荐
- FluCyD-vac含9 μg HA/株和20% w/v HP-β-CyD;Flu-vac含15 μg HA/株。
- FluCyD-vac的HA抗原量比Flu-vac少40%。
- 接种后21天FluCyD-vac组HI滴度与Flu-vac组相当并满足国际标准。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hydroxypropyl-β-cyclodextrin (HP-β-CyD), an oligosaccharide used as an excipient in pharmaceutical preparation, was recently reported to function as a vaccine adjuvant to co-administered antigens. In this study, we investigated the safety and immunogenicity of a seasonal influenza vaccine adjuvanted with HP-β-CyD (FluCyD-vac) in healthy adults compared with those of a standard seasonal influenza vaccine (Flu-vac). METHODS: We conducted a single-blinded randomized phase 1 clinical trial study, and used two quadrivalent split seasonal influenza vaccines: FluCyD-vac containing 9 μg of HA/strain and 20% w/v of HP-β-CyD, and Flu-vac containing 15 μg of hemagglutinin (HA)/strain only. All participants were randomly assigned to receive a single dose of Flu/CyD-vac or Flu-vac at a ratio of 2:1. We assessed solicited and unsolicited adverse events (AEs) and immune responses using hemagglutination inhibition (HI) titers. In addition, we assessed T-cell function in peripheral blood mononuclear cells (PBMCs), after stimulation with HA vaccine strains, using flow cytometry. RESULTS: Among 36 healthy volunteers enrolled in the study (FluCyD-vac, n = 24; Flu-vac, n = 12), FluCyD-vac was well tolerated. Most of the solicited AEs were mild local skin reactions at the injection site. No serious AEs were reported in either group. HI titers 21 days after vaccination with FluCyD-vac were comparable with those of Flu-vac and sufficient to meet international criteria, despite reduced HA antigen doses. When PBMCs were stimulated with the four HA antigens in the vaccine, tumor necrosis factor (TNF)-α-producing CD4+ T cells were enhanced in the FluCyD-vac group. CONCLUSION: FluCyD-vac was well-tolerated and immunogenic, despite containing 40% less HA antigens than Flu-vac. This study showed that HP-β-CyD is a potentially safe, novel adjuvant for human influenza vaccine. CLINICAL TRIAL REGISTRY: UMIN000028530.
引用
- Watanabe A, Nishida S, Burcu T, et al. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial. Vaccine. 2022. PMID: 35672178. doi:10.1016/j.vaccine.2022.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。